Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

United Therapeutics reports "unprecedented" Phase 3 success for Tyvaso in idiopathic pulmonary fibrosis

United Therapeutics (NASDAQ:UTHR), a public benefit corporation, today announced that its pivotal TETON-1 study evaluating nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.

Leia mais: United Therapeutics reports "unprecedented" Phase 3 success for Tyvaso in idiopathic pulmonary fibrosis
Grafa

Neumora Therapeutics reports Q4 and FY financial results and clinical program updates

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biotechnology company pioneering precision medicines for brain diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Leia mais: Neumora Therapeutics reports Q4 and FY financial results and clinical program updates
Grafa
Health

China approves GSK’s Exdensur as first semi-annual treatment for severe asthma

GSK (NYSE:GSK) today announced that China’s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype.

Leia mais: China approves GSK’s Exdensur as first semi-annual treatment for severe asthma
Grafa

Zymeworks receives FDA fast track designation for ZW191 in platinum-resistant ovarian cancer

Zymeworks (NASDAQ:ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191 for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).

Leia mais: Zymeworks receives FDA fast track designation for ZW191 in platinum-resistant ovarian cancer
Grafa
Energy

Leidos completes $2.4B acquisition of ENTRUST Solutions to bolster grid modernization

Leidos (NYSE:LDOS), a Fortune 500 innovation leader in defense, aviation, and information technology, announced today the successful completion of its acquisition of ENTRUST Solutions Group for approximately $2.4 billion.

Leia mais: Leidos completes $2.4B acquisition of ENTRUST Solutions to bolster grid modernization
Grafa
Health

IDEAYA Biosciences announces first patient dosed in Phase 1 IDE849 and IDE161 combination study

IDEAYA Biosciences (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the first-patient-in (FPI) for its Phase 1 clinical trial evaluating the combination of IDE849 and IDE161.

Leia mais: IDEAYA Biosciences announces first patient dosed in Phase 1 IDE849 and IDE161 combination study
Grafa

Nanobiotix lung cancer trial data shows 71% response rate at ELCC

NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches, today announced promising initial data from the Phase 2 CONVERGE study evaluating its lead candidate, JNJ-1900 (NBTXR3), in patients with stage 3 inoperable non-small cell lung cancer (NSCLC).

Leia mais: Nanobiotix lung cancer trial data shows 71% response rate at ELCC
Grafa
Technology

Bitdeer to build Norway’s largest AI data center featuring NVIDIA Vera Rubin tech

Bitdeer Technologies Group (NASDAQ:BTDR), a global leader in advanced computing and blockchain infrastructure, announced today that its subsidiary, Tydal Data Center AS (TDC), has officially engaged Data Center Installations AS (DCI) to develop a state-of-the-art 180 MW artificial intelligence data center in Tydal, Norway.

Leia mais: Bitdeer to build Norway’s largest AI data center featuring NVIDIA Vera Rubin tech